306 related articles for article (PubMed ID: 38247727)
1. Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature.
Huang C; Lau TW; Smoller BR
Dermatopathology (Basel); 2024 Jan; 11(1):26-51. PubMed ID: 38247727
[TBL] [Abstract][Full Text] [Related]
2. Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.
Griewank KG; Koelsche C; van de Nes JAP; Schrimpf D; Gessi M; Möller I; Sucker A; Scolyer RA; Buckland ME; Murali R; Pietsch T; von Deimling A; Schadendorf D
Clin Cancer Res; 2018 Sep; 24(18):4494-4504. PubMed ID: 29891723
[No Abstract] [Full Text] [Related]
3. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
4. Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects.
Blokx WA; van Dijk MC; Ruiter DJ
Histopathology; 2010 Jan; 56(1):121-32. PubMed ID: 20055910
[TBL] [Abstract][Full Text] [Related]
5. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
6. Primary Undifferentiated/Dedifferentiated Cutaneous Melanomas-A Review on Histological, Immunohistochemical, and Molecular Features with Emphasis on Prognosis and Treatment.
Țăpoi DA; Gheorghișan-Gălățeanu AA; Dumitru AV; Ciongariu AM; Furtunescu AR; Marin A; Costache M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373134
[TBL] [Abstract][Full Text] [Related]
7. β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors.
de la Fouchardière A; Caillot C; Jacquemus J; Durieux E; Houlier A; Haddad V; Pissaloux D
Virchows Arch; 2019 May; 474(5):539-550. PubMed ID: 30756182
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of cyclooxygenase-2 (COX-2) in oral nevi and melanoma.
de Souza do Nascimento J; Carlos R; Delgado-Azañero W; Mosqueda Taylor A; de Almeida OP; Romañach MJ; de Andrade BA
J Oral Pathol Med; 2016 Jul; 45(6):440-3. PubMed ID: 26608958
[TBL] [Abstract][Full Text] [Related]
9. Molecular testing for melanocytic tumors: a practical update.
Andea AA
Histopathology; 2022 Jan; 80(1):150-165. PubMed ID: 34958511
[TBL] [Abstract][Full Text] [Related]
10. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
11. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
12. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
13. E-Cadherin Expression in Canine Melanocytic Tumors: Histological, Immunohistochemical, and Survival Analysis.
Silvestri S; Porcellato I; Mechelli L; Menchetti L; Iussich S; De Maria R; Sforna M; Bongiovanni L; Brachelente C
Vet Pathol; 2020 Sep; 57(5):608-619. PubMed ID: 32578507
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry in melanocytic lesions: Updates with a practical review for pathologists.
Saleem A; Narala S; Raghavan SS
Semin Diagn Pathol; 2022 Jul; 39(4):239-247. PubMed ID: 35016807
[TBL] [Abstract][Full Text] [Related]
15. Black and Brown Oro-facial Mucocutaneous Neoplasms.
Natarajan E
Head Neck Pathol; 2019 Mar; 13(1):56-70. PubMed ID: 30693458
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic classification and prognostic factors of melanoma: a 2021 update.
Bobos M
Ital J Dermatol Venerol; 2021 Jun; 156(3):300-321. PubMed ID: 33982546
[TBL] [Abstract][Full Text] [Related]
17. Rate of Immunohistochemistry Utilization in the Diagnosis of Cutaneous Melanocytic Lesions.
Chen TC; Hitchcock MG
Am J Dermatopathol; 2021 Dec; 43(12):e146-e148. PubMed ID: 33795556
[TBL] [Abstract][Full Text] [Related]
18. Melanocytic precursors of cutaneous melanoma. Estimated risks and guidelines for management.
Rhodes AR
Med Clin North Am; 1986 Jan; 70(1):3-37. PubMed ID: 3510347
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
20. Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy.
Scolyer RA; Murali R; McCarthy SW; Thompson JF
Arch Pathol Lab Med; 2010 Dec; 134(12):1770-7. PubMed ID: 21128774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
